$12.53
+8.4%Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Chief Executive Officer, President & Director
Compensation
$943,020
Chief Scientific Officer
Compensation
$648,600
Chief Strategy & Financial Officer and Treasurer
Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
Executive Vice President, Head of Research & Development and Chief Medical Officer
Compensation
$721,087
Founder & Independent Director
Compensation
$48,125
General Counsel, Secretary & Compliance Officer
Senior Vice President of Biometrics
Senior Vice President of Clinical Development
Vice President & Head of Regulatory Affairs
During the last 12 months, there has been no insider trading activity reported for ELTX.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
No buying activity
No selling activity
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
No insider trading activity reported from any insiders in the past year.
ELTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 09, 2025 | April 09, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | September 27, 2024 | November 07, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 09, 2022 | 2022 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.